Pharmacology, Toxicology and Pharmaceutical Science
Prospective Cohort Study
100%
All Cause Mortality
93%
Chronic Kidney Failure
91%
Cardiovascular Disease
70%
Hemodialysis
47%
Cohort Study
42%
Remission
33%
Infection
28%
Vitamin D
26%
Vitamin D Receptor
26%
Disease
22%
Renin
21%
Angiotensin
21%
Proteinuria
21%
Secondary Hyperparathyroidism
20%
Observational Study
20%
Recombinant Erythropoietin
20%
Continuous Erythropoiesis Receptor Activator
19%
ANCA Associated Vasculitis
19%
Randomized Clinical Trial
19%
Ischemic Heart Disease
19%
Mortality Rate
17%
Adverse Event
15%
Kidney Disease
15%
Survival Rate
14%
Renin-Angiotensin System Inhibitor
14%
Nephrotic Syndrome
14%
Neutrophil Cytoplasmic Antibody
14%
Parathyroid Hormone
14%
Cause of Death
13%
Antianemic Agent
13%
Combination Therapy
13%
Angiotensin Receptor Antagonist
12%
Alfacalcidol
11%
Phosphate Binding Agent
11%
Vasculitis
11%
Human Study
11%
Nephrosclerosis
11%
End Stage Renal Disease
10%
Congestive Heart Failure
10%
Focal Glomerulosclerosis
10%
High Density Lipoprotein Cholesterol
10%
Serum Albumin
9%
Dicarbonate
9%
Glomerulonephritis
9%
Microangiopathy
9%
Arteriovenous Fistula
9%
Ferrous Sulfate
9%
Hyperuricemia
9%
Antihypertensive Agent
9%
Medicine and Dentistry
Chronic Kidney Disease
85%
All Cause Mortality
61%
Prospective Cohort Study
57%
Cardiovascular System
48%
Kidney Function
47%
Glomerular Filtration Rate
45%
Cohort Analysis
37%
Proteinuria
33%
End Stage Renal Disease
31%
Vascular Access
28%
Hazard Ratio
25%
Nephrology
25%
Hemodialysis
25%
Isotopes of Calcium
22%
Phosphate Binder
21%
Cardiovascular Disease
20%
Proportional Hazards Model
19%
Vitamin D Receptor
19%
Lipoprotein Apheresis
19%
ANCA Associated Vasculitis
19%
Aortic Valve Stenosis
19%
Analeptic
19%
Erythropoietin
19%
Retrospective Cohort Study
19%
Minimal Change Disease
19%
Creatinine
16%
Nephrotic Syndrome
16%
Hematinic
15%
Neutrophil Cytoplasmic Antibody
14%
Observational Study
14%
Serum Albumin
13%
Fibroblast Growth Factor 23
13%
Urinary System
13%
Mortality Rate
12%
Vasculitis
12%
Prevalence
12%
Nephropathy
12%
Myeloperoxidase
11%
Outpatient
11%
Infection
11%
Odds Ratio
11%
Renal Biopsy
11%
Congestive Heart Failure
11%
Combination Therapy
11%
Population
10%
Sodium Bicarbonate
10%
Recombinant Erythropoietin
10%
Malignant Neoplasm
10%
Human Study
10%
Prospective Study
10%
Keyphrases
Dialysis Initiation
53%
Multicenter Cohort Study
33%
Incident Dialysis Patients
28%
Dialysis
25%
Confidence Interval
23%
All-cause Mortality
21%
Prospective Cohort Study
21%
Dialysis Efficiency
20%
Japanese Patients
20%
Hazard Ratio
20%
Stage 5 Chronic Kidney Disease
19%
Malignancy
19%
Minimal Change Disease
19%
Remission of Proteinuria
19%
Japan
17%
Chronic Kidney Disease
17%
Remission
15%
Renin-angiotensin System Inhibitors
14%
Nephrotic Syndrome
14%
Infection-related Mortality
13%
ANCA-associated Vasculitis
12%
End-stage Kidney Disease
12%
Angiotensin Receptor Blockers
12%
Cardiovascular Disease
12%
Non-dialysis
11%
Cardiovascular Events
11%
Adult Patients
11%
PTH Level
10%
Clinical Outcomes
10%
Vitamin D Receptor Activator
10%
Darbepoetin Alfa
9%
Mass Quality
9%
Hemoglobin Level
9%
Outcome Analysis
9%
Sex Differences
9%
Phosphorus Levels
9%
Thrombotic Microangiopathy
9%
Vascular Access
9%
Ferrous Sulfate
9%
Ferric Citrate
9%
Hyperuricemia
9%
Evolocumab
9%
Maxacalcitol
9%
Parathyroid Glands
9%
Epoetin Alfa
9%
Maintenance Hemodialysis Patients
9%
Renal Anemia
9%
Baseline Trend
9%
Hb Level
9%
Continuous Erythropoietin Receptor Activator
9%
